Associated Papers
In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition.
Heidrich I et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.
Lenchner DS et al.
Npj Precision Oncology, 2024
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
36829178 (PubMed )
Supplement: 12916_2023_2768_MOESM1_ESM.docx
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
34599863 (PubMed )
Supplement: CAM4-10-7360-s002.xlsx › S2
Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.
Thirunavukarasu D et al.
Genome Biology, 2021
34482832 (PubMed )
Supplement: 13059_2021_2449_MOESM2_ESM.xlsx › NSCLC
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.
Mao L et al.
Pathology Oncology Research : Por, 2021
Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report.
Yang Y et al.
Frontiers in Oncology, 2020
The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients.
Li M et al.
Cancer Biology & Therapy, 2019
Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.
Nishikawa S et al.
Journal of Thoracic Disease, 2018
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
Ma W et al.
Molecular Diagnosis & Therapy, 2017
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.
Wu SG et al.
Erj Open Research, 2017
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Kis O et al.
Nature Communications, 2017
28492226 (PubMed )
Supplement: ncomms15086-s1.pdf
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.
Kitamura A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2010
Select a paper to view details